The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Swiss drug major Roche’s (SIX: ROG) subcutaneous RoActemra (tocilizumab) for use in Scotland in the treatment of rheumatoid arthritis.
The company sees this approval as particularly important for those in Scotland who live in rural and remote locations, far from hospitals, since subcutaneous RoActemra can be administered at hospital or home, unlike its intravenous formulation.
It is the first anti interleukin (IL)-6 receptor inhibitor for use with and without methotrexate, which provides a new option for patients who cannot or will not continue with methotrexate, which causes incomplete responses and/or adverse events in 20%-40% of patients. RoActemra/Actemra generated sales of 568 million Swiss francs ($628 million) in the first half of 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze